Loading...
Loading...
Goldman Sachs upgraded its prices target on Myriad Genetics
MYGN in a research report published today.
Goldman also upgraded its earnings per share forecast, after better than expected Q1 results, but reiterated its Sell rating on Myriad.
In the report, Goldman states, "MYGN reported revenues/EPS of $102mn/$0.31 vs. our $99mn/$0.26 estimate and Street $98mn/$0.25. BRCAnalysis sales of $90.3mn were ahead of our $87.5mn estimate, COLARIS sales were $7.4mn (GS: $6.9mn) and other sales totaled $4.7mn, slightly above our $4.4mn estimate. Management raised FY2011 guidance to $396 – 402mn/$1.06 – 1.09 from $380 – 400mn/$0.95 – 1.00 in EPS partially from the inclusion of Rules Based Medicine related revenues (~$2mn expected). In addition, MYGN
provided greater detail on its proposed acquisition of Rules Based Medicine and its go to market strategy in Europe. We revise our FY2011-2013 estimates to $1.08, 1.28, 1.45 from $1.02, 1.19, and 1.36 and raise our price target to $19 from $17."
Myriad's shares added 5.72% to their value today to stand at $22.56.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Analyst ColorPrice TargetAnalyst RatingsBiotechnologyGoldman SachsHealth CareMyriad Genetics
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in